Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Spyre Therapeutics, Inc.
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
May 22, 2026
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
May 21, 2026
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
May 21, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
May 20, 2026
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026
May 17, 2026
←
Previous Page
1
2